Pharmaceutical

Repare signs out-licensing deal with DCx Biotherapeutics

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms and IP.

May 2, 2025 - 06:00
Repare signs out-licensing deal with DCx Biotherapeutics
Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms and IP.
Read the original article

Tags:

Previous Article

PTSD market expected to reach $5.5bn across the 7MM by 2034

Next Article

Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘We’re absolutely making it too hard’: The complexity of adult immunization delivery hinders vaccine uptake

‘We’re absolutely making it too hard’: The complexity o...

Oct 26, 2023

Sun Pharma and Philogen sign licence agreement for anti-cancer therapy

Sun Pharma and Philogen sign licence agreement for anti...

May 30, 2023

STAT+: New Biden initiative targets controversial hospital ‘facility fees’ that often surprise patients

STAT+: New Biden initiative targets controversial hospi...

Jul 10, 2023